sorry, we can't preview this file
13075_2018_1582_MOESM1_ESM.docx (826.95 kB)
Additional file 1: of IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis
journal contribution
posted on 2018-06-07, 05:00 authored by Sungsin Jo, Sung Wang, Young Lee, Suman Kang, Bitnara Lee, Jinil Han, Il-Hoon Sung, Ye-Soo Park, Sang-Cheol Bae, Tae-Hwan KimFigure S1. Effect of osteogenic differentiation on both Ct-BdCs and AS-BdCs. Figure S2. Correlation of IL-17 levels in AS patients with ESR, CRP, and BASDAI levels. Figure S3. Correlation of IL-17 levels in RA patients with ESR and CRP levels. Figure S4. Secukinumab inhibits AS serum-induced phosphorylation status of JAK2/STAT3 in Ct-BdCs. Figure S5. Secukinumab suppresses IL-17A dose-dependent ALP activation in Ct-BdCs. Figure S6. Effect of JAK2 inhibitor (AG490) treatment on viability and toxicity of both Ct- and AS-BdCs. Table S1. Primer Sequences for qPCR. Table S2. Primary antibodies used in Immunoblotting (IB), Immunostaining (IF), and Immunohistochemistry (IHC). (DOCX 826 kb)